Description
Interleukin-2 is primarily used for the treatment of metastatic renal cell carcinoma and melanoma. It has not been approved by the FDA for use in colorectal cancer (CCR) and its role in CCR remains investigational; there are no established clinical guidelines or standard dosing regimens for this indication.
Mechanism of Action
Interleukin-2 (IL-2) is a cytokine that stimulates the growth, proliferation, and differentiation of T lymphocytes; it also enhances natural killer cell activity.
Side Effects
Hypotension; fever; chills; nausea; vomiting; anorexia; weight loss; fatigue; headache; insomnia; tachycardia; hyperventilation; fluid retention; pulmonary edema; pleural effusion; pericardial effusion; cardiac arrhythmias; myocarditis; heart failure; renal insufficiency; hepatic dysfunction; hyperglycemia; neutropenia; thrombocytopenia.
Not all side effects are listed. Side effects vary by individual. Always consult your oncologist.
Clinical Trials
NCT07001592
Phase 1
Recruiting
Intra-tumoral (IT) Injection of vvDD-hIL2-2-RG-1 for Metastatic Gastrointestinal and Peritoneal Tumors
United States